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Background: More research is needed to understand the contribution of comorbidities to MS 
symptomatology.  
Objectives: To examine the dose-response relationship between the number of comorbidities 
and severity of MS symptoms and to assess the relative contribution of comorbidity groups and 
individual comorbidities to the severity of each symptom.  
Methods: We surveyed 1,223 participants of the Australian MS Longitudinal Study for the 
presence of 30 comorbidities and the severity of 13 MS symptoms (0-10 scale). The 
associations between comorbidities and symptoms were assessed using negative binomial 
regression. The relative contributions of comorbidities to the severity of symptoms were 
assessed using general dominance analysis. 
Results:  Higher number of comorbidities was most strongly associated with a higher severity 
of pain and feelings of anxiety and depression (ratios of means >0.12 per comorbidity increase). 
Comorbidities explained between 3.7% (spasticity) and 22.0% (feelings of anxiety) of the total 
variance of symptom severity. Mental health and musculoskeletal disorders contributed most 
strongly to the severity of the most common symptoms in MS. 
Conclusions: Our findings support that early recognition and optimal management of 
comorbidities, particularly of mental health and musculoskeletal disorders, could have a 









Multiple sclerosis (MS) affects more than 2.5 million people worldwide and is considered one 
of the most common disabling neurological disorders.1  The symptomatology ranges from 
physical symptoms including vision loss, spasticity, bladder and bowel dysfunction, walking 
and balance problems, fatigue and pain to psychiatric issues like cognitive impairments, 
depression and anxiety.2, 3 Previous research showed the strong impact these symptoms have 
on the quality of life of people with MS.4 However, most of these symptoms are not specific to 
MS and could be related to other medical conditions.5 The majority of people with MS (PwMS) 
have comorbidities,6, 7 and understanding how comorbidities influence the symptomatology of 
MS could assist in guiding the management of symptoms in MS. 
Comorbidities make a substantial contribution to reduced quality of life and general well-being 
of PwMS.8 However, our understanding of the extent to which comorbidities influence the 
severity of different symptoms in MS is limited.9-11 In a cross-sectional study of 339 PwMS, 
the severity of common symptoms such as fatigue, balance problems and weakness was 
significantly higher in PwMS who had comorbidities such as depression, anxiety, migraine and 
coronary artery diseases compared to those without these comorbidities.9 In two longitudinal 
studies assessing the relationship between comorbidities and a single symptom (i.e. pain in one 
study10 and fatigue in the other11), the presence of comorbidities was associated with higher 
risk of experiencing these symptoms worsening over time.10, 11 As these studies included a 
limited number of symptoms and/or comorbidities, they were unable to assess the cumulative 
impact of multiple comorbidities on the severity of symptoms or assess which comorbidities 
had the largest influence on each symptom. This is an important evidence gap. 
Therefore, with data available from the Australian MS Longitudinal Study (AMSLS) on 30 
comorbidities and 13 most common symptoms in MS, the goals of this study were to: 1) 




examine the dose-response relationship between the number of comorbidities and severity of 
each symptom, and 2) assess the relative contribution of comorbidity groups and individual 




The AMSLS is a national sample of around 3,000 adult Australian volunteers with MS,12 of 
whom approximately 96% were diagnosed by a neurologist with definite MS using the 
McDonald criteria.13 It is an ongoing survey-based research project supported by MS societies 
in all Australian states and territories. Ethical approval for the study was initially given by the 
Australian Capital Territory Health Human Research Ethics Committee (HREC) and then by 
the Tasmanian Health and Medical HREC when the study centre was relocated to Tasmania in 
2014.  All participants provided informed consent. 
Data used for this study came from two surveys. To assess comorbidities, we used the 2016 
Lifestyle and Environment Survey ((August-October 2016); 3102 survey invitations sent and 
a total of 1,518 (49%; 1,067 online and 451 paper) responded). To assess the severity of 
common symptoms in MS, we used the 2016 Medication and Disease Course Survey 
((November 2016-March 2017); 3,098 survey invitations sent and a total of 1,699 (56%; 1,282 
online and 417 paper) responded). Those who completed both surveys (N=1,223) were 
included in the analysis.  
Measurements 
Comorbidities 
The participants were asked “Do you have or have you had this condition?” (Yes/No) for each 
of the 30 most frequently reported comorbidities in MS.6, 14, 15 If yes, the participant was coded 




as having that comorbidity and we subsequently asked: “Was it diagnosed by a doctor?” 
(Yes/No/Don’t know). If yes, the participant was coded as having that doctor-diagnosed 
comorbidity. The “Don’t know” group was combined with the “No” group. The total 
comorbidities (i.e. any comorbidity the patient reported having) and doctor-diagnosed 
comorbidities (i.e. any comorbidity the patient reported as diagnosed by a doctor) were 
counted. The comorbidities were grouped according to the 263 blocks (disease categories) in 
the International Classification of Diseases–10th revision (ICD-10) structure. Due to power 
considerations, we excluded comorbidities reported by less than 10 participants which 
excluded Parkinson’s disease and schizophrenia. The complete list of the 28 included 
individual comorbidities and the comorbidity groups to which they belong are shown in Figure 
1 and Table 3, respectively. 
Symptoms severity measures 
The severity of the 13 most common symptoms was assessed using the Multiple Sclerosis 
Symptom Scores (MSSymS) asking the participants to rate their average symptoms severity in 
the last four weeks compared to before they developed MS.16  MSSymS is a validated single-
item numeric rating scale of 0 to 10, wherein 0 corresponds to “having no (symptom) compared 
to before developing MS” and 10 equates to “worst possible (symptom), preventing many daily 
activities”.16 The complete list of symptoms is listed in Figure 1.  
Other measures 
MS duration was calculated by subtracting years since MS symptom onset or years since MS 
diagnosis from survey date. Body mass index (BMI) was calculated by dividing self-reported 
weight (in kilograms) by height2 (in centimetres). Disability was assessed using the Patient-
Determined Disease Steps Scale (PDDS), scored from 0 (no disability and only mild 
symptoms) to 8 (bedridden)) and a validated patient-reported instrument which has been 




strongly correlated with the Expanded Disability Status Scale (EDSS, r=0.78).17, 18 Data on sex, 
MS onset-type (i.e. relapse-onset and progressive-onset), disease modifying therapy status and 
education attainment were also obtained from the 2016 Medication and Disease Course Survey. 
Statistical analysis 
We used analysis of variance or ꭓ2 tests to compare the differences between the PwMS who 
were included and not included in the analysis. Associations between the number of 
comorbidities and the severity of common symptoms in MS was evaluated using negative 
binomial regression. A dose-response was assessed using a test for trend.  Potential 
confounders were identified by using causal diagrams and by examining whether the 
coefficient of each outcome (i.e. symptoms) variable was altered by more than 10% when a 
covariate (i.e. age, sex, MS duration, MS onset-type (relapse-onset vs. progressive-onset) and 
education level) was added to the model.19, 20  
We used linear regression with transformation to calculate the total variance (R2) explained by 
the predictors (i.e. comorbidities) on each symptom severity variable. We applied general 
dominance analysis (using the domin add-on module in Stata),21 as proposed by Azen and 
Budescu,22 to determine the relative contribution of each comorbidity group (categorized 
according to ICD-10) to the total variance (R2) of the severity of each symptom. In the groups 
with the highest contribution per symptom, the contribution of individual comorbidities 
belonging to that group was also determined. General dominance analysis provides an intuitive 
measure of predictor importance in two ways: 1) it uses the change in model fit (i.e., R2) to 
determine the contribution of each predictor and 2) it compares predictor contributions across 
all possible subset models from a given set of predictors.22, 23  Results were presented as general 
dominance weights, standardized to be out of 100%, to provide a ranking and weighting for 
each predictor in the model.22 To examine whether the results differed for comorbidities that 
were reported to be doctor-diagnosed, we conducted a sensitivity analysis by limiting our 




analysis to doctor-diagnosed comorbidities.  The significance level was set at p <0.05 (two-
tailed). All analyses were performed using STATA/IC for Windows (version 15.0; StataCorp 




The mean age of the total cohort was 56.1 and 78.7% of included participants were female 
(Table 1). The average MS duration since symptom onset was 20.5 years, 87.8% had relapse-
onset MS, 62.1% were currently taking disease modifying therapy and 36.5% had university 
degree or higher. More than half of the participants were either overweight (32%) or obese 
(26%) (as defined by BMI >25), and almost half of the participants had no to mild level of 
disability as defined by PDDS < 3 (47.6%). 
Non-response bias analyses comparing participants who were included with those who were 
not showed that those who were included were slightly older (+1.34 years; p <0.01) and had a 
slightly longer MS duration (+0.76 year; p =0.02), but there were no significant differences in 
sex (79% vs 76%; p = 0.72) and education attainment (37% respondents have university 
bachelor’s or postgraduate degree vs 34%; p = 0.18). 
Prevalence of comorbidities 
The most prevalent comorbidities were depression (42%), anxiety (39%), allergies (37%), 
hypertension (30%), migraine (28%), high cholesterol (24%), osteoarthritis (23%), eye 
diseases (15%), cancer (14%), anaemia (13%) and osteoporosis (13%) (Figure 1).  
Association between the number of comorbidities and severity of common symptoms in MS 




For PwMS without comorbidity, the mean symptom severity ranged from 1.6 (vision problems) 
to 4.2 (difficulty with balance) (Figure 2). For those with 5 or more comorbidities, mean 
symptom severity ranged from 2.9 (vision problems) to 5.8 (fatigue). After adjustment for 
confounders, the association between the number of comorbidities and symptom severity was 
strongest for feelings of anxiety, feelings of depression and pain. Significant associations were 
observed for 2 or more comorbidities and the mean severity of these symptoms was on average 
1.12 times to 1.13 greater for each additional comorbidity (Table 2) (Supplementary Table 1 
shows unadjusted analyses). Significant associations were also observed for the other 
symptoms, but only for those with a higher number of comorbidities (i.e. 3 or more for sensory 
symptoms, 4 or more for fatigue, 5 or more for other symptoms) and effect sizes were lower 
with adjusted average ratios of means per comorbidity ranging from 1.02 to 1.08 (Table 2). 
Relative contribution of comorbidity groups on the severity of common symptoms in MS 
The comorbidities together accounted for 3.7% (spasticity) to 22.0% (anxiety symptoms) of 
the variance for symptoms severity (Table 3). General dominance analysis showed that mental 
health disorders (i.e. a diagnosis of depression or anxiety) had the largest relative contribution 
to the severity of symptoms such as feeling of anxiety (weighting=87%), feelings of depression 
(85%), fatigue (42%), cognitive symptoms (66%), sensory symptoms (30%) and sexual 
dysfunction (35%) and made the second greatest contribution (>20%) to all other symptoms 
except bladder problems, walking difficulty and difficulty with balance. Musculoskeletal 
disorders had the largest relative contribution to the severity of the following symptoms: pain 
(30%), walking difficulties (41%), balance (35%), bladder (33%) and bowel (34%) problems 
and spasticity (45%). As would be expected, eye diseases (31%) had the largest relative 
contribution to vision problems of PwMS. 
Relative contribution of individual comorbidities on the severity of common symptoms in MS 




In the two comorbidity groups that had the largest contribution on the severity of common 
symptoms in MS (i.e. mental health disorders and musculoskeletal disorders), a diagnosis of 
depression had the largest relative contribution (28% or more) to feelings of depression, pain, 
fatigue, cognitive and sensory problems and sexual dysfunction and osteoporosis had the 
largest relative contribution (42% or more) to walking difficulties, balance, bladder and bowel 
problems and spasticity. A diagnosis of anxiety and eye diseases had the largest contribution 
to feelings of anxiety and vision problems, respectively (Table 4). 
Sensitivity analyses 
When we restricted our analyses to doctor-diagnosed comorbidities, we found similar 
associations between the number of comorbidities and the severity of common MS symptoms 
(Supplementary Figure 1 and Supplementary Tables 2 and 3). Similar patterns were also 
observed for the relative contribution of comorbidity groups and individual comorbidities to 
most MS symptoms except for pain (Supplementary Tables 4 and 5). For pain, mental health 
disorders (27%) rather than musculoskeletal disorders had the largest contribution.   
 
Discussion 
To the best of our knowledge, our study is the first to examine the relative contribution of a 
wide range of comorbidity groups on the severity of the most common symptoms in MS in 
order to identify which comorbidity groups and individual comorbidities had the biggest 
impact. In this large representative cohort of Australians with established MS, higher number 
of comorbidities was strongly associated with the severity of all MS symptoms, with the 
strongest associations being for symptoms of feelings of anxiety, feelings of depression and 
pain. This suggests that the severity of common MS symptoms could be heavily impacted by 
a higher comorbidity load of PwMS. Among all the comorbidity groups evaluated in this study, 




mental health and musculoskeletal comorbidities contributed most strongly to the severity of 
most MS symptoms, implying that an early detection of these comorbidities may be a viable 
strategy to substantially reduced symptoms severity in PwMS. Overall, our findings support 
the premise that early screening, optimal management and prevention of comorbidities, 
particularly of mental health and musculoskeletal disorders, could have a positive prognosis on 
the severity of symptom of PwMS.  
Comorbidities were prevalent, with ~91% having at least one comorbidity and ~27% having 
five or more comorbidities, which aligns with literature.6, 24 The total number of comorbidities 
seems to have the biggest potential to impact on feelings of anxiety, feelings of depression and 
pain because the number of comorbidities was most strongly associated with these three 
symptoms, with the mean severity being significantly higher for those with two or more 
comorbidities compared to those without comorbidities. The effect sizes were less strong for 
the other symptoms and frequently only significant effects were observed when comparing 
those with higher numbers of comorbidities to those without comorbidities (i.e. 3 or more for 
sensory symptoms, 4 or more for fatigue, 5 or more for vision problems, cognitive symptoms, 
sexual dysfunction, spasticity, bowel problems, walking difficulty), suggesting that these 
symptoms are predominantly impacted when people have a very high comorbidity load.   
Mental health disorders and musculoskeletal disorders had the largest relative contributions to 
the severity of common symptoms in MS. Interestingly, a companion paper in this issue shows 
that both mental health and musculoskeletal disorders were also the strongest contributors to 
lowering the health-related quality of life in people with MS in this same cohort.25 Mental 
health disorders (with a diagnosis of depression having the largest individual contribution) had 
the largest relative contribution to the severity of feelings of anxiety, feelings of depression, 
cognitive symptoms, sensory symptoms, fatigue and sexual dysfunction. Musculoskeletal 




disorders (with osteoporosis having the largest individual contribution) had the largest relative 
contribution to the severity of pain, walking difficulties, difficulty with balance, bladder 
problems, bowel problems and spasticity. Our findings align with the past literature in which 
mental health comorbidities, particularly a diagnosis of depression, were linked to higher 
severity of fatigue, disability and cognitive impairment.26 In one prospective study involving 
106 people with relapsing-remitting MS, a diagnosis of depression was more common and 
more severe in PwMS who reported fatigue symptoms.27 Further, previous studies showed that 
a diagnosis of depression may exacerbate cognitive impairment in PwMS28, 29 specifically for 
those with moderate to severe depression.30 Similarly, our results were consistent with other 
studies showing that musculoskeletal disorders contributes significantly to pain symptoms in 
PwMS.31, 32 Further, Marrie and colleagues previously showed that PwMS were more likely to 
have osteoporosis due to low bone density which further contribute to the severity of bone 
fractures, immobility, balance problems and pain.33  
Our findings indicate that it is important for clinicians to recognize the large impact of mental 
health and musculoskeletal disorders on the symptom severity in MS and to understand that 
the total number of comorbidities seem to have the biggest impact on feelings of anxiety, 
feelings of depression and pain. Understanding the interrelations between a patient’s 
cumulative impact of comorbidities and MS symptom load is an important step in deciding on 
the optimal management strategies. Our study does not aim to attribute causation. While it is 
likely that comorbidities add to the symptom load of a person with MS, the converse may also 
happen, particularly where a symptom is an important determinant of the diagnosis of a 
comorbidity (i.e. higher feelings of depression and the diagnosis of depression). Irrespective of 
this, our findings support that early detection and routine screening, particularly of mental 
health disorders and musculoskeletal disorders, throughout the disease course could be a viable 
strategy to prevent and minimise the impact of these comorbidities on MS symptoms. It is also 




important for clinician’s to be aware that medications for MS as well as comorbidities could 
have unwanted symptomatic side effects 5, 34. Comorbidity prevention and symptom reduction 
could be further assisted by empowering and assisting patients with a personalised approach 
around healthy lifestyle choices, such as following a healthy diet, maintaining adequate levels 
of physical activity and smoking cessation.  
Strengths of the study are the inclusion of broad range of comorbidities as well as most common 
MS symptoms, which also allowed us to group comorbidities and identify the relative 
contribution of these comorbidity groups and individual comorbidities for each symptom 
severity. Although the AMSLS is a highly representative sample of the MS population,12 some 
selection bias may have occurred as not all participants answered the two surveys. When we 
compared participants, those who were included with those not included, there were only small 
differences in age and MS duration and no significant differences in education attainment and 
sex were observed. Although we were incapable of comparing all MS-specific characteristics 
between the included and excluded participants, our study sample shows similar distributions 
in sex and MS onset-types when compared with other MS cohort studies,35 making our results 
likely generalisable to the whole MS population. Using patient-reported data on comorbidities 
allowed us to include comorbidities that may be under-reported in medical records or excluded 
in clinical settings (e.g. allergies, migraine and musculoskeletal diseases). A limitation was that 
it might have caused some measurement error. To address this, we also asked whether the 
comorbidities were doctor-diagnosed and found that the results were similar irrespective of 
whether we used total or doctor-diagnosed comorbidities.  
  




In conclusion, a higher number of comorbidities was most strongly associated with higher 
severity of most MS symptoms, particularly for feelings of anxiety, feelings of depression and 
pain. Mental health and musculoskeletal disorders were the strongest contributors to the 
symptom severity load. A deeper understanding of the relationships between comorbidities and 
symptoms, as provided in this study, is beneficial for the management of PwMS by clinicians. 
Our work suggests that mental health and musculoskeletal comorbidities should be targeted for 
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Table 1. Characteristics of the participants 
Characteristic Study sample (N = 1,223) 
Number of people with MS with no comorbidity 111 (9.1) 
Number of people with MS with at least 1 comorbidity 1,112 (90.9) 
Age (years), mean (SD) 56.1 (11.2) 
MS duration since symptom onset (years), mean (SD) 20.5 (10.7) 
MS duration since diagnosis (years), mean (SD) 15.2 (8.9) 
Sex, n (%)  
       Male 260 (21.3) 
       Female 963 (78.7) 
Currently on Disease Modifying Therapy, n (%)  
       Yes 759 (62.1) 
       No 464 (37.9) 
Disease course at onseta, n (%)  
       Relapse-onset Multiple Sclerosisb 862 (87.8) 
       Progressive-onset Multiple Sclerosisc 120 (12.2) 
Body mass indexd (kg/m2), n (%)  
      Normal (BMI = 18.5 to 24.9) 503 (42.5) 
      Overweight (BMI = 25 to 29.9) 376 (31.8) 
      Obese (BMI = 30 and over) 304 (25.7) 
Patient Determined Disease Steps (PDDS) (0-8), n (%)  
       No disability (PDDS score = 0) 293 (24.4) 
      Mild disability (PDDS score = 1-2) 278 (23.2) 
      Moderate disability (PDDS score = 3-5) 415 (34.6) 
      Severe disability (PDDS score > 6) 215 (17.9) 
Education attainment, n (%)  
      Primary and Secondary school  356 (29.3) 
      Occupational certificate/diploma 415 (34.2) 
      University bachelor’s degree 261 (21.5) 
      University postgraduate degree 182 (15.0) 
 
a Excluded those who ticked “unsure” (n = 139) and those who did not specify their MS onset type (n = 102); b Includes relapsing remitting 
multiple sclerosis and secondary progressive multiple sclerosis; c Includes primary progressive multiple sclerosis and progressive relapsing 
multiple sclerosis;  d Body mass index (BMI) was  calculated by dividing self-reported weight (in kilograms) by height2 (in centimetres). 





Figure 1. The prevalence of comorbidities in people with MS 
*Heart diseases include angina, congestive heart failure and coronary artery disease. 
 




Figure 2. The mean severity of common symptoms of people with MS per total comorbidity increase*  
*Each MS symptom severity was based from a 0 to 10 numeric rating scale wherein 0 = least severe to 10 = most severe. Total comorbidity refers to any comorbidity the participant reported having. 
 






Table 2. The adjusted ratios and average ratios of the means per total comorbiditya increase of people with MS 
No. Feelings of anxietyb 
Feelings of 
depressionb Pain

















Adjusted ratio of means per comorbidity increasei 
0 1.00 (Ref) 





























































































































p-value for trend 
 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p=0.01 p=0.02 p=0.07 




























a Total comorbidity refers to any comorbidity the participant reported having; b Ratios of means were adjusted by age; c Ratios of means were adjusted by MS onset-type; d Ratios of means were adjusted by age, sex and MS onset-type; e Ratios of means 
were adjusted by age and sex; f Ratios of means were adjusted by age and MS onset-type; g Ratios of means were adjusted by age and MS duration; h Ratios of means were adjusted by age, sex, MS onset-type and MS duration; i Adjusted ratios and 
average ratios of mean in bold font indicate significance at 95% confidence interval (CI). 































explained by all 
comorbidity groups 
(% R2) 
22.00 18.41 9.77 8.35 7.73 5.70 5.57 5.27 5.12 4.33 3.93 3.58 3.67 
  
Comorbidity groups                                             Standardized general dominance weightsj 
Circulatory disordersc 3.7 (2) 1.9 9.6  7.9 2.7 28.4 (2) 7.3 27.7 (2) 11.9 18.5 10.4 17.4 (2) 18.8  
Endocrine and 
metabolic disordersd 1.4 1.6 7.5 8.4  5.2  4.4 2.3 9.4 5.1 3.6 13.8  3.3 1.4 
Chronic renal disease 0.1 0.1 1.4 0.1 1.0 0.9 2.6 1.0 0.3 0.3 0.2 1.8 0.3 
Musculoskeletal 
disorderse 3.6 5.9 (2) 29.5 (1) 15.8 (2) 3.1 41.1 (1) 15.6 (2) 34.6 (1) 18.6 18.6 (2) 34.4 (1) 32.5 (1) 45.2 (1) 
Gastrointestinal 
disordersf 0.2 0.5 1.0 8.4 2.2 0.6 5.6 0.1 0.6 0.5 0.1 0.1 1.4 
Psoriasis 0.8 2.0 1.9 1.5 4.3 3.3 6.2 2.2 0.3 7.0 2.1 6.5 7.5 
Anaemias 0.3 0.5 0.3 0.8 0.8 3.7 8.1  1.7 0.7 3.5 2.6 0.3 0.8 
Nervous system 
disordersg 0.9 0.9 5.6 4.0 9.0 (2) 3.8 5.8 1.0 2.1 0.8 0.6 0.3 0.5 
Allergies 0.8 0.5 3.4 1.8 1.5 0.6 4.8 0.4 0.6 0.5 2.1 3.1 0.3 
Cancer 0.1 0.1 2.4 0.1 0.9 1.0 2.7 0.6 0.3 2.2 1.0 0.4 0.1 
Other autoimmune 
diseaseh 0.9 1.1 5.9 7.8 3.7 3.1 8.0 5.4 0.7 8.8 1.6 8.8 2.4 
Mental health 
disordersi 87.3 (1) 84.9 (1) 28.0 (2) 42.4 (1) 65.5 (1) 6.6  29.9 (1) 11.8  27.7 (2) 35.2 (1) 28.1 (2) 16.7  20.4 (2) 
Eye diseases 0.1 0.2 3.4 1.2 1.1 2.6 1.2 4.3 31.1 (1) 0.6 3.1 9.0 1.0 
 
a Based from the total comorbidities which refer to any comorbidity the participant reported having; bThe severity of each symptom was based from a 0 to 10 numeric rating scale wherein 0 = least severe to 10 = most severe; c Include hypertension, heart 
diseases, myocardial infarction, stroke and peripheral vascular diseases; d Include high cholesterol, type 1 diabetes, type 2 diabetes, hyperthyroidism and hypothyroidism; e Include osteoporosis, osteoarthritis, rheumatoid arthritis, systemic lupus 
erythematosus; f Include inflammatory bowel disease and coeliac disease; g Include epilepsy and migraine; h Include autoimmune diseases aside from MS; I Include depression and anxiety; j Standardized general dominance weight is the contribution of 
each comorbidity group to the overall R2 normed or standardized to be out of 100%. The shaded area highlights the 2 comorbidity groups with the highest contribution ranked. 






Table 4. Relative contribution of individual comorbiditiesa for each MS symptom severity - results from general dominance analysis 
Common 























groups Standardized general dominance weights
c 
Circulatory disorders 
   Hypertension 3.4 - - - - 15.0 (2) - 11.4 - - - 1.1 - 
   Heart diseases 0.3 - - - - 7.4 - 19.5 (2) - - - 23.3 (2) - 
Myocardial 
infarction 0.1 - - - - 2.1 - 2.7 - - - 2.3 - 
    Stroke 0.5 - - - - 0.9 - 0.4 - - - 3.7 - 
Peripheral 
vascular disease 0.2 - - - - 7.1 - 2.2 - - - 15.8 - 
Musculoskeletal disorders 
   Osteoporosis - 2.0 17.0 28.8 (2) - 59.0 (1) 25.8 (2) 50.3 (1) - 28.7 (2) 52.1 (1) 42.2 (1) 58.0 (1) 
   Osteoarthritis - 2.4 26.8 (2) 7.5 - 5.0 9.0 5.4 - 13.2 9.3 8.9 5.7 
Rheumatoid 
arthritis - 2.1 8.7 0.6 - 3.3 2.9 7.9 - 1.2 0.6 2.6 8.8 
Systemic lupus 
erythematosus - 0.7 4.8 1.3 - 0.2 6.9 0.3 - 5.2 4.1 0.2 2.9 
Nervous system disorders 
    Epilepsy - - - - 6.4  - - - - - - - - 
    Migraine - - - - 6.7 - - - - - - - - 
Mental health disorders 
    Depression 34.1 (2) 76.0 (1) 28.3 (1) 49.4 (1) 72.6 (1) - 41.4 (1) - 30.1 (2) 43.5 (1) 29.0 (2) - 21.0 (2) 
    Anxiety 61.4 (1) 16.7 (2) 14.5 12.3  14.3 (2) - 14.1 - 17.5  8.2 4.9 - 3.7 
Eye diseases - - - - - - - - 52.4 (1) - - - - 
 
a Based from the total comorbidities which refer to any comorbidity the participant reported having; b The severity of each symptom was based from a 0 to 10 numeric rating scale wherein 0 = least severe to 10 = most severe; c Standardized 
general dominance weight is the contribution of each comorbidity group to the overall R2 normed or standardized to be out of 100%. The shaded area highlights the 2 individual comorbidities with the highest contribution ranked. 





Supplementary Table 1. The unadjusted ratios and average ratios of the means per total comorbiditya increase of people with MS 



















Unadjusted ratio of means per comorbidity increaseb 
0 1.00 (Ref) 





























































































































p-value for trend 
 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 
Unadjusted average ratios of means per comorbidity increaseb 








































Supplementary Figure 1. The mean severity of common symptoms of people with MS per doctor-diagnosed comorbidity increase  
* The severity of each symptom was based from a 0 to 10 numeric rating scale wherein 0 = least severe to 10 = most severe. Doctor-diagnosed comorbidity refers to any comorbidity the patient reported as diagnosed 
by a doctor. 
 
 




Supplementary Table 2. The unadjusted ratios and average ratios of the means per doctor-diagnosed comorbiditya increase of people with MS 



















Unadjusted ratio of means per comorbidity increaseb 
0 1.00 (Ref) 





























































































































p-value for trend 
 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 
Unadjusted average ratios of means per comorbidity increaseb 



























a Doctor-diagnosed comorbidity refers to any comorbidity the patient reported as diagnosed by a doctor; b Unadjusted ratios and unadjusted average ratios of mean in bold font indicate significance at 95% confidence interval (CI). 
 







Supplementary Table 3. The adjusted ratios and average ratios of the means per doctor-diagnosed comorbiditya increase of people with MS 





















Adjusted ratio of means per comorbidity increasei 
0 1.00 (Ref) 





























































































































p-value for trend 
 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 p<0.01 P<0.01 P=0.01 p<0.01 p<0.01 p=0.02 p=0.07 p=0.04 
Adjusted average ratios of means per comorbidity increasei 



























a Doctor-diagnosed comorbidity refers to any comorbidity the patient reported as diagnosed by a doctor; b Ratios of means were adjusted by age; c Ratios of means were adjusted by MS onset-type; d Ratios of means were adjusted by age, sex and MS 
onset-type;e Ratios of means were adjusted by age and sex; f Ratios of means were adjusted by age and MS onset-type; g Ratios of means were adjusted by age and MS duration; h Ratios of means were adjusted by age, sex, MS onset-type and MS 
duration; i  Adjusted ratios and average ratios of mean in bold font indicate significance at 95% confidence interval (CI). 

































explained by all 
comorbidity groups 
(% R2) 
15.02 14.33 10.69 7.76 6.21 5.78 5.26 5.03 4.15 3.86 3.67 3.48 3.24 
  
Comorbidity groups                                             Standardized general dominance weightsj 
Circulatory 
disordersc 4.2 (2) 1.8 9.0 8.9 2.8 7.0 28.9 (2) 28.7 (2) 13.2 10.1 18.7 18.5 (2) 21.2 (2) 
Endocrine and 
metabolic disordersd 2.2 1.9 6.9 8.7 5.5 2.9 4.6 9.7 6.8 12.1 4.1 2.6 1.7 
Chronic renal disease 0.1 0.1 1.4 0.2 0.3 2.2 1.1 1.2 0.4 0.3 0.6 2.0 0.3 
Musculoskeletal 
disorderse 4.1 6.8 (2) 24.7 (2) 17.8 (2) 5.2 14.2 (2) 41.8 (1) 35.4 (1) 22.3 (2) 37.5 (1) 20.8 (2) 31.9 (1) 48.9 (1) 
Gastrointestinal 
disordersf 0.2 0.5 0.7 8.9 1.7 4.2 0.6 0.4 0.7 0.6 0.1 0.2 0.8 
Psoriasis 1.5 3.3 1.4 2.4 6.1 6.0 2.5 1.2 1.0 0.4 5.7 5.8 3.4 
Anaemia 0.5 0.8 0.3 0.7 1.4 6.5 5.6 2.7 0.7 1.2 6.1 0.2 1.4 
Nervous system 
disordersg 1.2 1.3 11.4 7.7 13.9 (2) 13.6 0.3 2.4 4.8 2.2 3.3 2.6 2.4 
Allergies 3.3 2.1 8.8 1.9 2.7 5.9 1.6 0.6 0.4 2.2 0.7 0.5 0.7 
Cancer 0.1 0.1 1.9 0.1 1.3 2.6 0.8 0.5 0.6 0.8 2.0 0.3 0.1 
Other autoimmune 
diseaseh 0.8 0.4 3.8 5.4 1.5 5.2 2.3 0.7 0.3 0.8 6.0 5.7 3.0 
Mental health 
disordersi 81.5 (1) 80.8 (1) 27.3 (1) 36.5 (1) 56.8 (1) 27.7 (1) 5.1 6.9 10.1 26.3 (2) 31.6 (1) 15.2 14.3 
Eye diseases 0.3 0.3 2.7 1.0 1.0 2.0 4.8 6.8 38.76 (1) 5.7 0.6 14.6 1.9 
 
a Doctor-diagnosed comorbidity refers to any comorbidity the patient reported as diagnosed by a doctor; b The severity of each symptom was based from a 0 to 10 numeric rating scale wherein 0 = least severe to 10 = most severe; c hypertension, heart 
diseases, myocardial infarction, stroke and peripheral vascular diseases; d Include high cholesterol, type 1 diabetes, type 2 diabetes, hyperthyroidism and hypothyroidism; e Include osteoporosis, osteoarthritis, rheumatoid arthritis, systemic lupus 
erythematosus; f Include inflammatory bowel disease and coeliac disease; g Include epilepsy and migraine; h Include autoimmune diseases aside from MS; I Include depression and anxiety; j Standardized general dominance weight is the contribution 
of each comorbidity group to the overall R2 normed or standardized to be out of 100%. The shaded area highlights the 2 comorbidity groups with the highest contribution ranked. 





Supplementary Table 5. Relative contribution of individua doctor-diagnosed comorbiditiesa for each MS symptom severity - results from general 
dominance analysis 
Common 
symptoms in MSb 
Feelings 
of anxiety  
Feelings of 
depression Pain


















groups Standardized general dominance weights
c 
Circulatory disorders 
    Hypertension 3.5 - - - - - 12.5 (2) 12.7 - - - 1.0 4.9 
    Heart diseases 0.5 - - - - - 11.2 20.1 (2) - - - 27.3 (2) 12.5 (2) 
    Myocardial 
infarction 0.2 - - - - - 2.2 3.2 - - - 3.5 1.1 
    Stroke 0.5 - - - - - 0.7 0.7 - - - 2.3 7.0 
Peripheral 
vascular disease 0.2 - - - - - 7.5 3.0 - - - 15.9 6.1 
Musculoskeletal disorders 
   Osteoporosis - 2.5 14.4 27.3 (2) - 21.2 (2) 56.5 (1) 45.2 (1) 9.8 53.7 (1) 26.3 (2) 38.2 (1) 52.2 (1) 
   Osteoarthritis - 2.6 25.0 (2) 8.1 - 10.0 5.9 7.2 16.6 (2) 10.2 16.7 7.8 5.3 
Rheumatoid 
arthritis - 3.0 9.3 2.0 - 4.5 3.4 7.7 9.7 0.3 1.4 3.8 8.5 
   Systemic lupus 
erythematosus - 0.6 3.9 1.6 - 5.7 0.2 0.2 3.8 3.2 4.7 0.3 2.5 
Nervous system disorders 
   Epilepsy - - - - 4.1 - - - - - - - - 
   Migraine - - - - 11.0 (2) - - - - - - - - 
Mental health disorders 
   Depression 43.8 (2) 77.8 (1) 32.1 (1) 45.5 (1) 78.6 (1) 45.9 (1) - - - 28.7 (2) 46.9 (1) - - 
   Anxiety 51.4 (1) 13.7 (2) 15.4 15.4 6.4 13.1 - - - 3.9 4.0 - - 
Eye diseases - - - - - - - - 60.1 (1) - - - - 
 
a Doctor-diagnosed comorbidity refers to any comorbidity the patient reported as diagnosed by a doctor; b The severity of each symptom was based from a 0 to 10 numeric rating scale wherein 0 = least severe to 10 = most severe; c Standardized 
general dominance weight is the contribution of each comorbidity group to the overall R2 normed or standardized to be out of 100%. The shaded area highlights the 2 individual comorbidities with the highest contribution ranked. 
